Cell Reports (Jan 2023)

GDF15 neutralization restores muscle function and physical performance in a mouse model of cancer cachexia

  • Ja Young Kim-Muller,
  • LouJin Song,
  • Brianna LaCarubba Paulhus,
  • Evanthia Pashos,
  • Xiangping Li,
  • Anthony Rinaldi,
  • Stephanie Joaquim,
  • John C. Stansfield,
  • Jiangwei Zhang,
  • Andrew Robertson,
  • Jincheng Pang,
  • Alan Opsahl,
  • Magalie Boucher,
  • Danna Breen,
  • Katherine Hales,
  • Abdul Sheikh,
  • Zhidan Wu,
  • Bei B. Zhang

Journal volume & issue
Vol. 42, no. 1
p. 111947

Abstract

Read online

Summary: Cancer cachexia is a disorder characterized by involuntary weight loss and impaired physical performance. Decline in physical performance of patients with cachexia is associated with poor quality of life, and currently there are no effective pharmacological interventions that restore physical performance. Here we examine the effect of GDF15 neutralization in a mouse model of cancer-induced cachexia (TOV21G) that manifests weight loss and muscle function impairments. With comprehensive assessments, our results demonstrate that cachectic mice treated with the anti-GDF15 antibody mAB2 exhibit body weight gain with near-complete restoration of muscle mass and markedly improved muscle function and physical performance. Mechanistically, the improvements induced by GDF15 neutralization are primarily attributed to increased caloric intake, while altered gene expression in cachectic muscles is restored in caloric-intake-dependent and -independent manners. The findings indicate potential of GDF15 neutralization as an effective therapy to enhance physical performance of patients with cachexia.

Keywords